RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and ChinaMay 10, 2023 - Eli Lilly’s Lilly chief scientific and medical officer Daniel Skovronsky is openly attacking a controversial clause in the new drug pricing law saying the law will discourage investments in small molecules.
I think that Skovronsky needs to read my opinion piece on this matter in which I outlined how the IRA will provide biologics 13 years of FDA market exclsusivity on approval, whereas small molecules will only be granted 9 years of FDA market exclusivity, primarily because the US Federal Government wants to protect next generation (NxG) biopharmaceutical intellectual propery and not have such biological IP shipped off-shore to be capitalized by India and China, as has occurred with small molecules and biosimilars.
ONCY's pelareorep is set to have a net-benefit from the recently passed IRA.
https://www.fiercepharma.com/pharma/lilly-exec-blasts-iras-nonsensical-chemical-biologics-disparity-drugmakers-ready-legal